390570729213/24/2023 11:04:34 PM3/24/2023 11:04:34 PMA Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in of either Malignant Pleural/Peritoneal Mesothelioma (MPM), Serous Ovarian STS_ListItem_GenericListhttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx5720https://www.uhn.caFalsehttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research{5E1D6FEA-DFB5-4E35-898A-FB5FF464140D}~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js4242
390433730943/24/2023 11:10:50 PM3/24/2023 11:10:50 PMA Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary cell and adenocarcinoma) 8. Mesothelioma (pleural and peritoneal STS_ListItem_GenericListhttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx5110https://www.uhn.caFalsehttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research{69DAF378-DF18-4595-94F9-39B55A981DAE}~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js4242
390416541823/24/2023 11:02:41 PM3/24/2023 11:02:41 PMA Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab for Participants With Advanced Solid Tumors STS_ListItem_GenericListhttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx3620https://www.uhn.caFalsehttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research{48534183-1023-4945-8D45-CBB846B359C0}~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js4242
390368215043/24/2023 10:59:40 PM3/24/2023 10:59:40 PMA Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects Small Cell Lung Carcinoma - Mesothelioma - Thyroid Carcinoma STS_ListItem_GenericListhttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx1430https://www.uhn.caFalsehttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research{A05F7CFB-3FEA-459E-B1F3-A09BD71B2717}~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js4242
3904252301073/24/2023 11:08:45 PM3/24/2023 11:08:45 PMA Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Malignant pleural mesothelioma - Small cell lung cancer STS_ListItem_GenericListhttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx220https://www.uhn.caFalsehttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research{A2DF8BD8-1376-44EB-A478-41D1354E6AA6}~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js4242
3905961186513/24/2023 11:10:03 PM3/24/2023 11:10:03 PMAn Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and MTC), gastroesophageal cancer (GEC), mesothelioma, breast cancer (BC) and STS_ListItem_GenericListhttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx3520https://www.uhn.caFalsehttps://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research{E5E39B7D-F663-406C-8667-A63A1EF8C899}~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js4242

~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js

Last reviewed:
Last modified: 6/15/2021 11:04 AM